Skip to main content

Drug Interactions between cycloserine and Jynarque

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between cycloserine and Jynarque. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

cycloserine

A total of 42 drugs are known to interact with cycloserine.

Jynarque

A total of 352 drugs are known to interact with Jynarque.

Drug and food interactions

Major

cycloSERINE food

Applies to: cycloserine

GENERALLY AVOID: Coadministration with alcohol may potentiate some of the central nervous system adverse effects of cycloserine and its prodrug, terizidone. These effects may include dizziness, drowsiness, depression, anxiety, psychoses, memory impairment, confusion, and convulsions.

MANAGEMENT: Patients should be advised to avoid the consumption of alcohol during treatment with cycloserine or terizidone. The use of these medications is contraindicated in patients with chronic alcohol consumption or alcoholism.

MONITOR CLOSELY: Coadministration with caffeine may potentiate some of the central nervous system adverse effects of cycloserine and its prodrug, terizidone. These effects may include insomnia, excitability, irritability, anxiety, tremor, psychoses, and convulsions.

MANAGEMENT: Caution is advised when cycloserine or terizidone is used with caffeine. Consumption of certain beverages or stimulants with very high caffeine levels should be avoided as a precautionary measure.

References (2)
  1. (2001) "Product Information. Seromycin (cycloserine)." Dura Pharmaceuticals
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
Moderate

tolvaptan food

Applies to: Jynarque (tolvaptan)

GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of tolvaptan. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. According to the product labeling, administration of tolvaptan with grapefruit juice resulted in a 1.8-fold increase in tolvaptan systemic exposure. The clinical significance is unknown, although increased pharmacologic effects may be expected. Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death.

MANAGEMENT: Patients treated with tolvaptan should avoid consumption of grapefruits and grapefruit juice.

References (1)
  1. (2009) "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.